MD Anderson’s Lee Named Medical Director of Texas Center for Proton Therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ANDREW LEE was named medical director of the Texas Center for Proton Therapy, a collaboration of Texas Oncology, Baylor Health, McKesson Specialty Health, and The US Oncology Network, effective Feb. 1.

Lee was a professor in the Department of Radiation Oncology at MD Anderson Cancer Center, working there for over 13 years. He was medical director of MD Anderson’s Proton Therapy Center, and served as director of advanced technologies. He was recognized as a recipient of The University Cancer Foundation Faculty Achievement Award in Patient Care.


Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.